Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2,3-Dihydroxybenzoylserine** is a small molecule and a derivative of L-serine in which the amino group is acylated with a 2,3-dihydroxybenzoyl group. It is naturally produced by certain bacteria such as *Escherichia coli* as part of their siderophore biosynthesis pathways. Siderophores are molecules that bind and transport iron in microorganisms. Specifically, this compound serves as a building block for catecholate-type siderophores like enterobactin and related analogs. Its primary biological function involves chelation of ferric iron (Fe^3+), facilitating iron acquisition under conditions of low environmental iron availability[1][5][4]. The mechanism involves strong binding to Fe^3+, forming stable complexes that can be transported into bacterial cells via specific receptors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,3-dihydroxybenzoylserine.